Provention Bio’s Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients

-One Course of Teplizumab Now Shown to Delay Insulin-Dependent T1D by a Median of Approximately Three Years Compared to Placebo- -Teplizumab Significantly Reversed the Decline in C-Peptide Levels Providing Further Evidence of Disease-Modifying Effect- -Extended Follow-up Results from the Pivotal "At-Risk" TN-10 Study Presented at the American Diabetes Association's 80th Scientific Sessions-

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here